Turnover: EUR ()
Country: France
With its pioneering technological advances in diabetes management, Grenoble-based start-up Diabeloop is doing its utmost to make innovation accessible to families affected by type 1 diabetes. To achieve this, the company has benefited from a combination of medical, algorithmic and technological expertise since 2011.
Diabeloop is best known for having marketed France's first artificial pancreas powered by complex algorithms, replacing traditional insulin pumps in 2015.
News
Diabeloop: Sanofi and Biocorp for the connected insulin pen 26/04/2023
- Diabeloop created in 2015.
- Cooperation agreement signed with Sanofi and Biocorp.
- 160 employees at Diabeloop.
- 250,000 people with type 1 diabetes (T1DM) in France.
- 20 million people with T1DM worldwide.
- 10% of the world's population affected by type 2 diabetes (T2DM).
- 11,500 patients in Europe currently using the DBLG1 system.
- The partnership also covers the DBL-4 pen product.
- Diabeloop hopes to have several hundred thousand or even millions of patients on board by 2030.
- Current sales under 10 million euros
- 70 million euros raised last June, a third of which for the US market.
Financial Data
DUNS: 810416438
Legal Name: DIABELOOP
Address: 155 CRS BERRIAT 155-157, 38000 GRENOBLE
Number of employees: 50 employés (2018)
Capital: 1 006 095 EUR
Financial Data:
| Year | Turnover (€) | Net Profit (€) | Fiscal Year End | Fiscal Year Duration |
|---|---|---|---|---|
| 2018 | 0 EUR | -250 570 EUR | 31/12/2018 | 12 |
| 2017 | 0 EUR | 137 104 EUR | 31/12/2017 | 12 |
Company Managers:
| Position | First Name | Last Name | Age | |
|---|---|---|---|---|
| Président du conseil d'administration | Guillaume | CHARPENTIER | 75 | |
| Directeur général | Erik Henk Jan | HUNEKER | 48 |